| 000 | 01393 a2200337 4500 | ||
|---|---|---|---|
| 005 | 20250518034335.0 | ||
| 264 | 0 | _c20200327 | |
| 008 | 202003s 0 0 eng d | ||
| 022 | _a1938-0682 | ||
| 024 | 7 |
_a10.1016/j.clgc.2019.03.009 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aHsu, Miles M | |
| 245 | 0 | 0 |
_aPD-1/PD-L1 Combinations in Advanced Urothelial Cancer: Rationale and Current Clinical Trials. _h[electronic resource] |
| 260 |
_bClinical genitourinary cancer _c06 2019 |
||
| 300 |
_ae618-e626 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, N.I.H., Extramural; Review | ||
| 650 | 0 | 4 |
_aAntineoplastic Agents, Immunological _xpharmacology |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xpharmacology |
| 650 | 0 | 4 |
_aB7-H1 Antigen _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aCarcinoma, Transitional Cell _xdrug therapy |
| 650 | 0 | 4 | _aClinical Trials as Topic |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aProgrammed Cell Death 1 Receptor _xantagonists & inhibitors |
| 650 | 0 | 4 | _aSurvival Analysis |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aTumor Microenvironment _xdrug effects |
| 650 | 0 | 4 |
_aUrologic Neoplasms _xdrug therapy |
| 700 | 1 | _aBalar, Arjun V | |
| 773 | 0 |
_tClinical genitourinary cancer _gvol. 17 _gno. 3 _gp. e618-e626 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.clgc.2019.03.009 _zAvailable from publisher's website |
| 999 |
_c29608647 _d29608647 |
||